title: [Long-standing therapy of the metabolic syndrome in diabetics after coronary artery bypass surgery].
abstract: Patients with type 2 diabetes often also exhibit additional features of the metabolic syndrome. These include specifically central obesity triggering development and maintenance of diabetes together with arterial hypertension, hypertriglyceridemia and low levels of high-density lipoprotein cholesterol. Chronic therapy of the metabolic syndrome in diabetics after coronary bypass surgery focuses on changes in lifestyle, i.e., cessation of smoking, changes in nutrition and increase in physical activity. Nutrition aims at fat reduction and modification to reduce saturated fatty acids, to allow mono- and polyunsaturated fatty acids instead, and moderate alcohol consumption. High fiber and complex carbohydrate diet complete the recommendations. Nutrition therapy connected to increases in physical activity are aimed at reducing weight in overweight and obese subjects, which should reduce their body weight by 5 to 10% within about 6 months. Normal weight subjects benefit from increases in physical activity by lipid and glucose regulation as well as by reduction in mortality.Diabetes-specific therapy aims at normoglycemia including postprandial blood glucose levels, reduces blood pressure supported by ACE inhibitors and aims at weight reduction. Reduction of LDL-cholesterol is the first line therapy, also diminishing small-dense LDL particles. Decreasing triglycerides and increasing HDL-cholesterol are further lipid-regulating aims. Specifically diabetics after coronary bypass surgery need LDL-cholesterol levels below 70 mg/d (1.8 mmol/L) and triglycerides below 150 mg/dL (1.7 mmol/L). In addition, in males HDL-cholesterol should be at least above 40 mg/dl (1 mmol/L), in females above 50 mg/dL (1.3 mmol/L).
authors.affiliation: St. Nikolaus-Stiftshospital GmbH, Hindenburgwall 1, 56626 Andernach. armin.steinmetz@stiftshospitalandernach.de
authors.forename: A
authors.initials: A
authors.lastname: Steinmetz
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001026:Coronary Artery Bypass; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D050171:Dyslipidemias / Q000150:complications; D015444:Exercise; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D009765:Obesity / Q000150:complications; D012737:Sex Factors; D016540:Smoking Cessation
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose